Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer

Abstract

One-hundred and seventy patients with estrogen receptor positive (≥10 pmol/g protein) advanced breast cancer have been treated in a prospective randomized study either with continuous tamoxifen 30 mg × 1 daily (TAM), or with TAM 30 mg × 1 daily for 8 weeks alternating with medroxyprogesterone acetate 500 mg × 2 daily for 8 weeks (TAM/HD-MPA). The response rate was 62% in the group treated with cyclic TAM/HD-MPA versus 41% in the TAM alone group (p = 0.02). There was no significant difference in duration of remissions or survival.

DOI: 10.1007/BF01812683

6 Figures and Tables

Statistics

050100'97'99'01'03'05'07'09'11'13'15'17
Citations per Year

83 Citations

Semantic Scholar estimates that this publication has 83 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Gundersen1990CyclicalUO, title={Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer}, author={Stein Gundersen and St. Kvinnsland and Sofie Lundgren and Olbjoern Klepp and Eiluv Lund and Ole Petter B\ormer and Herman H\ost}, journal={Breast Cancer Research and Treatment}, year={1990}, volume={17}, pages={45-50} }